EIGER BIOPHARMACEUTICALS INC (EIGR) Stock Price, Forecast & Analysis
USA - NASDAQ:EIGR - US28249U2042 - Common Stock
EIGR Key Statistics, Chart & Performance
The current stock price of EIGR is 1.725 USD. In the past month the price decreased by -70.76%. In the past year, price decreased by -94.72%.
EIGR Latest News, Press Relases and Analysis
EIGR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.85 | 381.38B | ||
| AMGN | AMGEN INC | 13.6 | 159.73B | ||
| GILD | GILEAD SCIENCES INC | 15.02 | 152.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.29 | 108.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.95 | 66.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 830.33 | 55.51B | ||
| ARGX | ARGENX SE - ADR | 62 | 51.19B | ||
| INSM | INSMED INC | N/A | 38.63B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.99 | 33.96B | ||
| NTRA | NATERA INC | N/A | 26.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.20B | ||
| BIIB | BIOGEN INC | 8.92 | 21.89B |
Related stock screener links
About EIGR
Company Profile
Eiger BioPharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Palo Alto, California and currently employs 56 full-time employees. The company went IPO on 2014-01-30. Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.
Company Info
EIGER BIOPHARMACEUTICALS INC
2155 Park Blvd
Palo Alto CALIFORNIA 94306 US
CEO: David A. Cory
Employees: 56
Phone: 16502799845
EIGER BIOPHARMACEUTICALS INC / EIGR FAQ
Can you describe the business of EIGER BIOPHARMACEUTICALS INC?
Eiger BioPharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Palo Alto, California and currently employs 56 full-time employees. The company went IPO on 2014-01-30. Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.
What is the current price of EIGR stock?
The current stock price of EIGR is 1.725 USD. The price decreased by -9.21% in the last trading session.
Does EIGR stock pay dividends?
EIGR does not pay a dividend.
What is the ChartMill rating of EIGER BIOPHARMACEUTICALS INC stock?
EIGR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting EIGR stock to perform?
8 analysts have analysed EIGR and the average price target is 91.8 USD. This implies a price increase of 5221.74% is expected in the next year compared to the current price of 1.725.
Can you provide the sector and industry classification for EIGER BIOPHARMACEUTICALS INC?
EIGER BIOPHARMACEUTICALS INC (EIGR) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of EIGER BIOPHARMACEUTICALS INC (EIGR) based on its PE ratio?
EIGER BIOPHARMACEUTICALS INC (EIGR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.49).
EIGR Technical Analysis
EIGR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EIGR. Both the profitability and financial health of EIGR have multiple concerns.
EIGR Financial Highlights
Over the last trailing twelve months EIGR reported a non-GAAP Earnings per Share(EPS) of -10.49. The EPS decreased by -348.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -193.08% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EIGR Forecast & Estimates
8 analysts have analysed EIGR and the average price target is 91.8 USD. This implies a price increase of 5221.74% is expected in the next year compared to the current price of 1.725.
For the next year, analysts expect an EPS growth of 68.29% and a revenue growth 37.05% for EIGR